Geron Announces Conference Call on September 12 at 8:00 A.M. Eastern Time

MENLO PARK, Calif., Sept. 11, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will host a conference call on September 12, 2016, at 8:00 a.m. Eastern Time to provide an update on the imetelstat Phase 2 trial in myelofibrosis and Phase 2/3 trial in myelodysplastic syndromes. Participants can access the conference call live via telephone by dialing 877-303-9139 … [Read more...]

Zosano Announces Inducement Grant for Georgia Erbez, Chief Business Officer

FREMONT, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company’s proprietary transdermal delivery system, today announced that it has approved an inducement grant of options to purchase 252,000 shares of the Company’s common stock with an exercise pri … [Read more...]

Intuitive Surgical Reports New Employee Option Grants for September 2016

SUNNYVALE, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG) today reported that equity awards approved by the Compensation Committee of the Board of Directors, which consists entirely of Independent Directors, were made to 86 new employees. Pursuant to NASDAQ Marketplace Rule 5635(c)(4), the equity awards were granted under the Intuitive … [Read more...]

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that its new Vice President of Corporate Communications and Investor Relations, Martin Forrest, received a grant of an option to purchase 31,875 shares of the company's common stock, at a per share exercise price of $16.13, the closing trading price on September … [Read more...]

Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented in a Rapid Fire Abstract Session at … [Read more...]